Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
69
resultados
Última actualización
05/10/2026 [06:45:00]
Resumen de: WO2026200437A1
Disclosed in the present invention are a Menin-MLL inhibitor, a preparation method therefor and the use thereof. The inhibitor can be used for the treatment of related diseases (in particular, hematological tumors (such as leukemia) and diabetes), and has excellent application prospects and research value.
Resumen de: US20260295033A1
An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.
Resumen de: WO2026202706A1
The present invention provides compounds of Formula I:, I which are useful for the inhibition of KAT6A, KAT6B, and/or KAT7. Compounds of Formula I are useful for the treatment of cancer, including bladder cancer, breast cancer, cervical cancer, colorectal cancer including colon and rectal adenocarcinomas, leukemias including acute myeloid leukemia (AML), lung adenocarcinoma, medulloblastoma, osteosarcoma, ovarian cancer, and prostate cancer.
Resumen de: US20260297031A1
0000 In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit breakpoint cluster region, chromosome 22 (BCR) and Abelson proto-oncogene 1, chromosome 9 (ABL1) in a subject, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant BCR and ABL1 activity. In another aspect, the compounds described herein can evade P-gp-mediated efflux in a subject, which makes the compounds effective in treating a Philadelphia chromosome positive (Ph+) leukemia.
Resumen de: WO2026207156A1
Anti-B-cell maturation antigen (BCMA) binding domains and uses thereof are provided. The binding domains can be used to target such cells expressing BCMA ex vivo or in vivo for research, diagnostic, or therapeutic purposes, for example in the treatment of multiple myeloma.
Resumen de: US20260294951A1
0000 The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and/or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.
Resumen de: US20260297156A1
0000 The present invention relates to the field of immunotherapy, in particular, adoptive T cell therapy of MAGEA1-associated cancer. TCR alpha chain constructs (TRA) and/or a TCR beta chain constructs (TRB) of TCR constructs specific for an epitope in complex with a human MHC-I, wherein the epitope is an epitope of a MAGEA1 protein, nucleic acids encoding them and host cells expressing them. The invention also provides pharmaceutical compositions or kits based theron. The invention teaches combinations of TCR constructs directed to different epitopes from the same antigen expressed by the same cancer or infectious agent capabel of being presented by different MHC-I molecules, wherein optionally, the antigen is MAGEA1. Preferably, at least one of the TCR constructs used in the combination is a TCR construct of the invention disclosed herein. The pharmaceutical combinations or kits may be used for immunotherapy of a subject, e.g., adoptive T cell therapy or TCR gene therapy, e.g., for use in treatment of a cancer such as lung cancer, colorectal cancer, or multiple myeloma. The invention also provides peptides comprising the epitopes recognized by the TCR constructs of the invention, which may be for use in vaccination, e.g., peptide vaccination or RNA vaccination.
Resumen de: US20260294921A1
0000 The present application discloses specific compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and their use in therapy, in particular, their use as human polymerase theta (Polθ) inhibitors for the treatment of hyperproliferative diseases including cancers such as carcinoma, sarcoma, adenocarcinoma, leukemia, lymphoma, and melanoma, and pre-malignant conditions. The application further discloses the use of a compound of formula (I), in combination with an additional anticancer therapy.
0000
Resumen de: US20260297147A1
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector including the nucleic acid molecule, a host cell including the expression vector or the genome integrated with the nucleic acid molecule, a preparation method therefor and a pharmaceutical composition thereof. Further provided is the use of the above-mentioned product, such as keratin YK93-2 in the preparation of a drug for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroid, prostatic hyperplasia etc.
Resumen de: US20260297148A1
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a preparation method for the keratin YK93-5, and a pharmaceutical composition of the keratin YK93-5, and further provides a use of the products such as the keratin YK93-5 in the preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroids, prostatic hyperplasia, etc.
Resumen de: US20260294848A1
0000 The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Resumen de: EP4813380A1
The present invention relates to the use of the alkyl phospholipid edelfosine (especially (S)-edelfosine) in the treatment of multiple myeloma.
Resumen de: WO2025108429A1
A chimeric antigen receptors (CARs) and CAR-NK cells targeting both BCMA and GPRC5D and use thereof in treating multiple myeloma (MM) is provided. In particular, the disclosure relates to bi-specific CARs comprising: (a) a B-cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor of family C, group 5, member D (GPRC5D) targeting domain, preferably armored with such as IL15, and the corresponding coding polynucleotides for the CARs and vectors comprising the polynucleotides. Also provided is CAR-NK cell modified with the CAR (s), and use of the CAR and CAR-NK cell in the treatment of MM.
Resumen de: EP4813396A2
Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
Resumen de: US20260286007A1
0000 Aspects of the disclosure provide anti-TMPRSS6 antibodies and methods of using the same for promoting hepcidin expression, and treating iron overload associated conditions, such as hemochromatosis, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), blood transfusion.
Resumen de: US20260284212A1
0000 Provided herein are human Cluster of Differentiation 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human CD6 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat T-cell related diseases (e.g., cancer, such as T-cell lymphoma). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions.
Resumen de: AU2026220660A1
The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.
Resumen de: AU2025255746A1
The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).
Resumen de: WO2026198571A1
The present disclosure concerns methods and compositions related to sdAbs targeting cyclin. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of cyclin is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of acute myeloid leukemia and other cancers that express cyclin.
Resumen de: WO2026198634A1
The invention provides an invariant natural killer T (iNKT) cell-targeted microparticle recruitment and activation system (iMRAS), one which provides a biomimetic platform that enhances iNKT cell functionality through localized immunostimulation in vivo. This biomimetic platform is designed to function as an in vivo "charging station" containing chemotactic and activation signals for the recruitment, activation, and expansion of CAR-iNKT cells, leading to more effective tumor killing and longer persistence of CAR-iNKT cells, as demonstrated in lymphoma and melanoma. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumors, establishing a robust platform for enhancing systemic CAR-iNKT cell-mediated immunotherapy.
Resumen de: WO2026198989A1
Provided herein are modified cystatin M/E (CST6) polypeptides or fragments thereof comprising a mutation as well as polynucleotide constructs encoding the same or cells comprising the same. Chimeric Antigen Receptor (CAR) T cells expressing the modified CST6 polypeptide are also provided. The disclosure further encompasses methods for use in treatment of cancer including multiple myeloma and methods of inhibiting or reducing bone loss using the compositions provided herein. Methods of maintaining CAR T cells receptor expression and methods of inducing immune responses using the compositions are also provided.
Resumen de: WO2026195557A1
A therapeutic composition is described containing CIK (Cytokine-Induced Killer) cells engineered to express a Chimeric Antigen Receptor (CAR) against an antigen present on acute myeloid leukaemia cancer cells and at least one interleukin-8 (IL-8) receptor. Other aspects of the invention relate to the engineered CIK cells and the use thereof in the treatment of acute myeloid leukaemia.
Resumen de: WO2026198924A1
The present invention describes ROR1 peptide binders and chimeric antigen receptor (CAR) cells expressing these binders. Also described are methods of producing T-lymphocyte (T-cell) expressing the CARs, and method of producing a natural killer (NK) cell expressing the CARs. Further described are methods of eliminating ROR1 positive cells and methods of eliminating myeloma cells, pancreatic cancer cells, or lymphoma cells. Methods of treating ROR1 positive cancers are also described herein.
Resumen de: WO2026198533A1
The present disclosure concerns methods and compositions related to sdAbs targeting BCMA. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of BCMA is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of multiple myeloma (MM) and/or B-cell lymphoproliferative disorders and other cancers that express BCMA.
Nº publicación: WO2026198551A1 24/09/2026
Solicitante:
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Resumen de: WO2026198551A1
The present disclosure concerns methods and compositions related to sdAbs targeting GPRC5D and FCRH5. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of GPRC5D or FCRH5 is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of multiple myeloma (MM) and/or B-cell lymphoproliferative disorders and other cancers that express GPRC5D or FCRH5.
BOPI
Sede Electrónica
